Key Highlights
- NeoGenomics has been in momentum since raising its full-year 2026 Revenue and adjusted EBITDA guidance following second quarter results.
- Total second-quarter revenue rose 11 percent year-over-year to USD 201.7 million, approximately USD 4 million above prior guidance.
- NGS revenue increased 26 percent year-over-year, accounting for about one-third of clinical revenue.
- Adjusted EBITDA increased 36 percent year-over-year to USD 14.4 million.
A Precision Oncology Diagnostics Company
Headquartered in Fort Myers, Florida, NeoGenomics is a genetic testing and precision medicine company providing testing services for oncology, reproductive health, and other indications. The company's offerings span cancer genetic testing, prenatal screening, and pharmacogenomics, with a growing focus on next-generation sequencing panels and minimal residual disease testing through its PanTracer and RaDaR ST product lines.
NGS Growth and Pricing Gains Drove the Guidance Raise
NeoGenomics reported total second-quarter revenue of USD 201.7 million, up 11 percent year-over-year and approximately USD 4 million above the company's previous guidance. Clinical revenue increased 14 percent, supported by a 12 percent rise in average revenue per test and a 2 percent increase in test volumes. NGS revenue increased 26 percent year-over-year and now accounts for about one-third of clinical revenue, with adjusted EBITDA increasing 36 percent to USD 14.4 million on the back of higher pricing, Volume leverage, and efficiency gains.
A Guidance Raise Reinforced Confidence in the Mix Shift
The stock's move to a fresh high reflects sustained momentum since NeoGenomics raised its full-year revenue guidance to USD 802 million to USD 806 million, as the company's shift from targeted gene panels toward comprehensive genomic profiling continues to drive both volume and pricing gains, a trend management described as durable given ongoing opportunities in payer contract improvements.
Reimbursement Expansion for RaDaR ST Represents the Next Growth Lever
Continued expansion of Medicare reimbursement for RaDaR ST, the company's tumor-informed MRD test, could unlock meaningful additional growth if pending indications receive favorable coverage decisions expected near the end of 2026 and into 2027. The combined therapy-selection and MRD markets addressed by the company's PanTracer and RaDaR portfolio represent an estimated USD 33 billion opportunity, though near-term volume comparisons will remain affected by the prior-year exit from a high-volume, low-value contract.
Conclusion
NeoGenomics' move to a 52-week high reflects sustained investor confidence following a guidance raise driven by accelerating next-generation sequencing growth and improving margins. Expanding reimbursement for the company's RaDaR ST minimal residual disease test represents a meaningful additional growth catalyst ahead. Continued momentum will likely depend on sustained AUP gains and successful reimbursement expansion across the company's precision oncology testing portfolio.






Please wait processing your request...